Healthcare provider profile · identity verified

Nari Sohn, MD

Family Practice · ROCHESTER, MN · NPI 1982263034

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	348	94
Levothyroxine Sodium	Levothyroxine Sodium	221	59
Lisinopril	Lisinopril	189	59
Losartan Potassium	Losartan Potassium	177	61
Omeprazole	Omeprazole	163	44
Amlodipine Besylate	Amlodipine Besylate	146	46
Metoprolol Succinate	Metoprolol Succinate	139	46
Hydrochlorothiazide	Hydrochlorothiazide	134	39
Simvastatin	Simvastatin	134	43
Gabapentin	Gabapentin	129	41
Rosuvastatin Calcium	Rosuvastatin Calcium	108	26
Sertraline Hcl	Sertraline Hcl	98	25
Trazodone Hcl	Trazodone Hcl	76	22
Bupropion Xl	Bupropion Hcl	67	17
Metoprolol Tartrate	Metoprolol Tartrate	64	12
Metformin Hcl Er	Metformin Hcl	60	18
Metformin Hcl	Metformin Hcl	58	16
Pantoprazole Sodium	Pantoprazole Sodium	52	15
Atenolol	Atenolol	50	16
Eliquis	Apixaban	50	12
Escitalopram Oxalate	Escitalopram Oxalate	50	20
Alendronate Sodium	Alendronate Sodium	47	14
Ozempic	Semaglutide	45	suppressed
Furosemide	Furosemide	44	17
Fluticasone Propionate	Fluticasone Propionate	43	23
Warfarin Sodium	Warfarin Sodium	43	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	42	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Famotidine	Famotidine	38	11
Tamsulosin Hcl	Tamsulosin Hcl	38	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	14
Pravastatin Sodium	Pravastatin Sodium	36	11
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Ezetimibe	Ezetimibe	35	suppressed
Pregabalin	Pregabalin	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	28	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	suppressed
Glipizide Er	Glipizide	27	11
Alprazolam	Alprazolam	26	12
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Chlorthalidone	Chlorthalidone	25	11
Phenytoin Sodium Extended	Phenytoin Sodium Extended	25	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Carvedilol	Carvedilol	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	suppressed
Baclofen	Baclofen	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Naproxen	Naproxen	17	12
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Cephalexin	Cephalexin	16	12
Ketoconazole	Ketoconazole	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Lorazepam	Lorazepam	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Xifaxan	Rifaximin	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Finasteride	Finasteride	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Repatha Sureclick	Evolocumab	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error